Exelixis Inc (EXEL) 3.29 $EXEL
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Apr 09, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
European Commission Approves Exelixis Inc.'s Therapy for Thyroid Cancer
ACCESSWIRE - Fri Apr 04, 1:00PM CDT
Exelixis Inc. (NASDAQ:EXEL) enjoyed robust stock volume Apr. 3, with 4,756,727 shares changing hands.
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
Morning Movers in Biotech: Celgene Corporation, Mylan, Inc. and Exelixis, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Apr 04, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Celgene Corporation , Mylan , and Exelixis . Mylan up on possible takeover of rival Swedish Pharma Shares of drugmaker Mylan are up over 11% in...
Are These 3 Biotechs Bad News Buys?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
March wasn't kind to many of biotech's hottest names. From Geron to Exelixis , many of biotech's most talked-about stocks suffered headache-inducing falls over the past month. Biotech's had a good run lately with the market's rise, and while...
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 02, 9:43AM CDT
Biotech companies continued to witness a decline in share prices last week.
Exelixis Continues On
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 6:42PM CDT
Shares of Exelixis got hit hard last week after the company said its clinical trial testing Cometriq in prostate cancer would continue. While the continuation of a trial would normally be a non-event -- we'll get the final data before the end of...
Hot Stock: Exelixis, Shares Gain 5.2% (EXEL)
Comtex SmarTrend(R) - Mon Mar 31, 10:12AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 5.2% to $3.56 on 1.6x average daily volume. Exelixis has traded 7.4 million shares thus far today, vs. average volume of 4.6 million shares per day. The stock has outperformed the Dow (5.2% to the Dow's 0.7%) and outperformed the S&P 500 (5.2% to the S&P's 0.8%) during today's trading.
Which Biotech Blow-Up Is a Bad-News Buy?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Mar 30, 1:00PM CDT
On this edition of Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass take a look at two of the weeks biggest biotech losers, and why one of them could make an interesting buy today. Shares of Exelixis were...
5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun Mar 30, 7:30AM CDT
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. Company March 28 Weekly Loss Exelixis $3.38 46% MannKind ...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 29, 7:00AM CDT
Spring might have sprung this week, but plenty of investors aren't feeling warm and fuzzy. That's especially the case for shareholders of this week's three horrendous health0care stocks. One of these stocks disappointed the market by simply...
Why Red Hat, Caesars Entertainment, and Exelixis Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 28, 7:30PM CDT
Favorable economic news helped send the stock market higher despite the usual pre-weekend jitters on Wall Street, as larger gains earlier in the day gave way to traders once again choosing not to hold onto positions in light of geopolitical...
Exelixis Inc's Comet Fails To Dazzle
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Mar 28, 8:30AM CDT
Astronomers have grown very cautious over the years about predicting which comets will brighten the night skies, as all too many have failed to live up to expectation. Small biotech Exelixis ' own comet, the COMET-1 study of cabozantinib in...
Exelixis' Cometriq Approved in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:00PM CDT
Exelixis received approval for Cometriq in the EU for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).
Trade-Ideas: Exelixis (EXEL) Is Today's "Dead Cat Bounce" Stock
at The Street - Thu Mar 27, 8:45AM CDT
Trade-Ideas LLC identified Exelixis (EXEL) as a "dead cat bounce" (down big yesterday but up big today) candidate
King Digital Crushed In Its First Day of Trading; Exelixis Shares Fall 40 Percent
ACCESSWIRE - Wed Mar 26, 11:11PM CDT
King Digital Entertainment Plc (NYSE: KING) - For an in-depth report on King Digital Entertainment Plc follow: www.BullTrends.com/stockquote/KING
Why Exelixis, ReneSola, and Capstone Turbine Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Mar 26, 7:30PM CDT
On Wednesday, stock market investors saw renewed fears about the sustainability of the five-year-old bull market, as heightened tensions between Russia and Ukraine contradicted the hopes that the conflict would quietly fade after Russia's annexation...
Talk About High Clinical Trial Expectations
Brian Orelli, The Motley Fool - Motley Fool - Wed Mar 26, 6:32PM CDT
Exelixis fell nearly 40% today on word that the company was continuing its phase 3 trial testing Cometriq in prostate cancer patients after the Independent Data Monitoring Committee took an interim peek at the data. On the surface, the news...
Why Exelixis, Inc., Plug Power Inc., and King Digital Entertainment PLC Are Today's 3 Worst Stocks
Dan Carroll, The Motley Fool - Motley Fool - Wed Mar 26, 6:00PM CDT
A down day for the markets couldn't stop three of today's big losers. The S&P 500 took a beating late in the day following renewed concerns over European and American sanctions against Russia. The index dropped 0.7% after a fine start to the...
Nasdaq stocks posting largest volume increases
AP - Wed Mar 26, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Apr 09, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
European Commission Approves Exelixis Inc.'s Therapy for Thyroid Cancer
ACCESSWIRE - Fri Apr 04, 1:00PM CDT
Exelixis Inc. (NASDAQ:EXEL) enjoyed robust stock volume Apr. 3, with 4,756,727 shares changing hands.
Why I Bought Exelixis
Sean Williams, The Motley Fool - Motley Fool - Fri Apr 04, 11:05AM CDT
Some days as a biotech investor, no matter how savvy you think you are, you just have to bury your head in the sand because you're bound to experience a bad day. That's what happened last week to shareholders of Exelixis , a company I've been very...
Morning Movers in Biotech: Celgene Corporation, Mylan, Inc. and Exelixis, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Apr 04, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Celgene Corporation , Mylan , and Exelixis . Mylan up on possible takeover of rival Swedish Pharma Shares of drugmaker Mylan are up over 11% in...
Are These 3 Biotechs Bad News Buys?
Dan Carroll, The Motley Fool - Motley Fool - Thu Apr 03, 8:30AM CDT
March wasn't kind to many of biotech's hottest names. From Geron to Exelixis , many of biotech's most talked-about stocks suffered headache-inducing falls over the past month. Biotech's had a good run lately with the market's rise, and while...
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 02, 9:43AM CDT
Biotech companies continued to witness a decline in share prices last week.
Exelixis Continues On
Brian Orelli, The Motley Fool - Motley Fool - Mon Mar 31, 6:42PM CDT
Shares of Exelixis got hit hard last week after the company said its clinical trial testing Cometriq in prostate cancer would continue. While the continuation of a trial would normally be a non-event -- we'll get the final data before the end of...
Hot Stock: Exelixis, Shares Gain 5.2% (EXEL)
Comtex SmarTrend(R) - Mon Mar 31, 10:12AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 5.2% to $3.56 on 1.6x average daily volume. Exelixis has traded 7.4 million shares thus far today, vs. average volume of 4.6 million shares per day. The stock has outperformed the Dow (5.2% to the Dow's 0.7%) and outperformed the S&P 500 (5.2% to the S&P's 0.8%) during today's trading.
Which Biotech Blow-Up Is a Bad-News Buy?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Sun Mar 30, 1:00PM CDT
On this edition of Market Checkup , Motley Fool health-care analysts David Williamson and Michael Douglass take a look at two of the weeks biggest biotech losers, and why one of them could make an interesting buy today. Shares of Exelixis were...
5 of Last Week's Biggest Losers
Rick Munarriz, The Motley Fool - Motley Fool - Sun Mar 30, 7:30AM CDT
There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers. Company March 28 Weekly Loss Exelixis $3.38 46% MannKind ...
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Mar 29, 7:00AM CDT
Spring might have sprung this week, but plenty of investors aren't feeling warm and fuzzy. That's especially the case for shareholders of this week's three horrendous health0care stocks. One of these stocks disappointed the market by simply...
Why Red Hat, Caesars Entertainment, and Exelixis Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri Mar 28, 7:30PM CDT
Favorable economic news helped send the stock market higher despite the usual pre-weekend jitters on Wall Street, as larger gains earlier in the day gave way to traders once again choosing not to hold onto positions in light of geopolitical...
Exelixis Inc's Comet Fails To Dazzle
Stephen D., Simpson,, The Motley Fool - Motley Fool - Fri Mar 28, 8:30AM CDT
Astronomers have grown very cautious over the years about predicting which comets will brighten the night skies, as all too many have failed to live up to expectation. Small biotech Exelixis ' own comet, the COMET-1 study of cabozantinib in...
Exelixis' Cometriq Approved in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:00PM CDT
Exelixis received approval for Cometriq in the EU for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).
Trade-Ideas: Exelixis (EXEL) Is Today's "Dead Cat Bounce" Stock
at The Street - Thu Mar 27, 8:45AM CDT
Trade-Ideas LLC identified Exelixis (EXEL) as a "dead cat bounce" (down big yesterday but up big today) candidate
King Digital Crushed In Its First Day of Trading; Exelixis Shares Fall 40 Percent
ACCESSWIRE - Wed Mar 26, 11:11PM CDT
King Digital Entertainment Plc (NYSE: KING) - For an in-depth report on King Digital Entertainment Plc follow: www.BullTrends.com/stockquote/KING
Why Exelixis, ReneSola, and Capstone Turbine Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Wed Mar 26, 7:30PM CDT
On Wednesday, stock market investors saw renewed fears about the sustainability of the five-year-old bull market, as heightened tensions between Russia and Ukraine contradicted the hopes that the conflict would quietly fade after Russia's annexation...
Talk About High Clinical Trial Expectations
Brian Orelli, The Motley Fool - Motley Fool - Wed Mar 26, 6:32PM CDT
Exelixis fell nearly 40% today on word that the company was continuing its phase 3 trial testing Cometriq in prostate cancer patients after the Independent Data Monitoring Committee took an interim peek at the data. On the surface, the news...
Why Exelixis, Inc., Plug Power Inc., and King Digital Entertainment PLC Are Today's 3 Worst Stocks
Dan Carroll, The Motley Fool - Motley Fool - Wed Mar 26, 6:00PM CDT
A down day for the markets couldn't stop three of today's big losers. The S&P 500 took a beating late in the day following renewed concerns over European and American sanctions against Russia. The index dropped 0.7% after a fine start to the...
Nasdaq stocks posting largest volume increases
AP - Wed Mar 26, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
